ProKidney Corp. (PROK) NASDAQ
1.93
+0.075(+4.05%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.93
+0.075(+4.05%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.89 |
| Day High | 1.96 |
| Day Low | 1.77 |
| 52-Week High | 7.13 |
| 52-Week Low | 0.54 |
| Volume | 1.9M |
| Average Volume | 899,987 |
| Market Cap | 647.29M |
| PE | -3.63 |
| EPS | -0.53 |
| Moving Average 50 Days | 1.85 |
| Moving Average 200 Days | 2.28 |
| Change | 0.08 |
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:30 PM GMT
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO,
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
GlobeNewswire Inc.
Nov 06, 2025 4:00 PM GMT
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted in a 4.6 mL
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
Oct 29, 2025 11:30 AM GMT
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior m